BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22491505)

  • 1. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis.
    Mistro S; Maciel Ide M; de Menezes RG; Maia ZP; Schooley RT; Badaró R
    Clin Infect Dis; 2012 Jun; 54(12):1774-7. PubMed ID: 22491505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Clin Infect Dis; 2013 Dec; 57(12):1783-4. PubMed ID: 24140972
    [No Abstract]   [Full Text] [Related]  

  • 3. Minimizing nephrotoxicity using continuous infusion of deoxycholate amphotericin B.
    Gwee A; Cranswick N; Connell TG; Curtis N
    Pediatr Infect Dis J; 2014 Oct; 33(10):1098. PubMed ID: 25361191
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipid formulations of polyene antifungal drugs and attenuation of associated nephrotoxicity.
    Razzaque MS; Hossain MA; Ahsan N; Taguchi T
    Nephron; 2001 Nov; 89(3):251-4. PubMed ID: 11598385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent acute tubular toxicity after switch from conventional amphotericin B to liposomal amphotericin B (Ambisome).
    Gerbaud E; Tamion F; Girault C; Clabault K; Lepretre S; Leroy J; Bonmarchand G
    J Antimicrob Chemother; 2003 Feb; 51(2):473-5. PubMed ID: 12562731
    [No Abstract]   [Full Text] [Related]  

  • 6. Nephrotoxicity in the setting of invasive fungal diseases.
    Ullmann AJ
    Mycoses; 2008; 51 Suppl 1():25-30. PubMed ID: 18471158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex.
    Craddock C; Anson J; Chu P; Dodgson A; Duncan N; Gomez C; Mehta J; Sadullah S; Subudhi C; Yin JL
    Expert Opin Drug Saf; 2010 Jan; 9(1):139-47. PubMed ID: 19947901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
    Bes DF; Rosanova MT; Sberna N; Arrizurieta E
    Pediatr Infect Dis J; 2014 Aug; 33(8):e198-206. PubMed ID: 24618932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply to Messori et al.
    Mistro S; Schooley RT; Badaro R
    Clin Infect Dis; 2013 Dec; 57(12):1784-5. PubMed ID: 24140973
    [No Abstract]   [Full Text] [Related]  

  • 10. Liposomal amphotericin B for fever and neutropenia.
    Patel MA; Curtis K; Maguire JH
    N Engl J Med; 1999 Oct; 341(15):1153; author reply 1154-5. PubMed ID: 10515752
    [No Abstract]   [Full Text] [Related]  

  • 11. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-based formulations of amphotericin B.
    Plotnick AN
    J Am Vet Med Assoc; 2000 Mar; 216(6):838-41. PubMed ID: 22570893
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
    Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
    Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.
    Steimbach LM; Tonin FS; Virtuoso S; Borba HH; Sanches AC; Wiens A; Fernandez-Llimós F; Pontarolo R
    Mycoses; 2017 Mar; 60(3):146-154. PubMed ID: 27878878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?
    Karimzadeh I; Farsaei S; Khalili H; Dashti-Khavidaki S
    Expert Opin Drug Saf; 2012 Nov; 11(6):969-83. PubMed ID: 22950480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms and management of amphotericin B-induced nephrotoxicity.
    Miano-Mason TM
    Cancer Pract; 1997; 5(3):176-81. PubMed ID: 9171554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
    Falci DR; da Rosa FB; Pasqualotto AC
    Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute renal failure with amphotericin B in lipid emulsion.
    Gales MA; Gales BJ; Alford KM
    Ann Pharmacother; 1996 Sep; 30(9):1036. PubMed ID: 8876871
    [No Abstract]   [Full Text] [Related]  

  • 19. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotoxicity of amphotericin B desoxycholate.
    Girmenia C; Gentile G; Micozzi A; Martino P
    Clin Infect Dis; 2001 Sep; 33(6):915-6. PubMed ID: 11512101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.